Dr Long Highlights Long-Term Benefit of Dabrafenib/Trametinib in Melanoma
Source: Targeted Oncology, March 2025
Georgina V. Long, MD, MSc, discussed the long-term follow-up data for the combination of adjuvant dabrafenib and trametinib in stage III BRAF-mutated melanoma.
The combination of dabrafenib (Tafinlar) and trametinib (Mekinist) led to sustained survival benefits as an adjuvant treatment vs placebo when given for the treatment of patients with stage III melanoma, according to over 8 years of follow-up in the COMBI-AD trial (NCT01682083).
Presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting and published in The New England Journal of Medicine, the final analysis revealed durable improvements in relapse-free survival (RFS) and distant metastasis-free survival, though the overall survival and melanoma-specific survival benefits did not reach statistical significance.